PL1809742T3 - Sposoby leczenia stawów związanych z gromadzeniem nadmiaru macierzy pozakomórkowej - Google Patents
Sposoby leczenia stawów związanych z gromadzeniem nadmiaru macierzy pozakomórkowejInfo
- Publication number
- PL1809742T3 PL1809742T3 PL05812977T PL05812977T PL1809742T3 PL 1809742 T3 PL1809742 T3 PL 1809742T3 PL 05812977 T PL05812977 T PL 05812977T PL 05812977 T PL05812977 T PL 05812977T PL 1809742 T3 PL1809742 T3 PL 1809742T3
- Authority
- PL
- Poland
- Prior art keywords
- accumulation
- methods
- extracellular matrix
- conditions associated
- treating conditions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/488—Aspartic endopeptidases (3.4.23), e.g. pepsin, chymosin, renin, cathepsin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/952,361 US7763580B2 (en) | 1999-01-05 | 2004-09-27 | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
PCT/US2005/034787 WO2006037029A2 (en) | 2004-09-27 | 2005-09-27 | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
EP05812977.6A EP1809742B1 (en) | 2004-09-27 | 2005-09-27 | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
Publications (1)
Publication Number | Publication Date |
---|---|
PL1809742T3 true PL1809742T3 (pl) | 2016-01-29 |
Family
ID=36119564
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL05812977T PL1809742T3 (pl) | 2004-09-27 | 2005-09-27 | Sposoby leczenia stawów związanych z gromadzeniem nadmiaru macierzy pozakomórkowej |
Country Status (7)
Country | Link |
---|---|
US (2) | US7763580B2 (pl) |
EP (1) | EP1809742B1 (pl) |
AU (1) | AU2005289518A1 (pl) |
CA (1) | CA2581980A1 (pl) |
ES (1) | ES2548725T3 (pl) |
PL (1) | PL1809742T3 (pl) |
WO (1) | WO2006037029A2 (pl) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6918226B2 (en) * | 2003-07-03 | 2005-07-19 | Rebecca A. Heilman | Automatic utensil wrapping machine |
JP5070200B2 (ja) * | 2005-04-22 | 2012-11-07 | イーライ リリー アンド カンパニー | Tgfベータ1に特異的な抗体 |
JP6199558B2 (ja) | 2009-12-23 | 2017-09-20 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | イヌにおける腎障害を診断し、そして治療するための組成物および方法 |
ES2715177T3 (es) * | 2010-09-01 | 2019-06-03 | Genzyme Corp | Tratamiento de infarto de miocardio usando antagonistas de tgf-beta |
ES2590263T3 (es) | 2011-02-24 | 2016-11-21 | Hill's Pet Nutrition, Inc. | Composiciones y métodos para el diagnóstico de trastornos renales en un felino |
WO2012167261A2 (en) | 2011-06-03 | 2012-12-06 | Yale University | Compositions and methods for treating and preventing neointimal stenosis |
EP2917336B1 (en) | 2012-11-09 | 2018-06-27 | Marco Archetti | Diffusible factors and cancer cells |
KR102258457B1 (ko) | 2013-03-11 | 2021-05-31 | 젠자임 코포레이션 | 조작된 항-tgf-베타 항체 및 항원-결합 단편 |
WO2017100782A1 (en) | 2015-12-11 | 2017-06-15 | Research Institute At Nationwide Children's Hospital | Systems and methods for optimized patent specific tissue engineering vascular grafts |
CN110191718A (zh) | 2016-12-15 | 2019-08-30 | 泰伦基国际有限公司 | 一种预防和治疗组织器官纤维化的方法 |
US11938172B2 (en) | 2017-06-19 | 2024-03-26 | Talengen International Limited | Method for regulating and controlling GLP-1/GLP-1R and drug |
WO2019133950A1 (en) * | 2017-12-30 | 2019-07-04 | The Regents Of The University Of Colorado, A Body Corporate | Smad7 for treatment and prevention of posterior capsule opacification |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5571714A (en) * | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
DK0494264T3 (da) | 1989-09-29 | 1998-01-26 | Jolla Cancer Res Found | Inhibering af transformede vækstfaktor til hindring af akkumulation af ekstracellulær matrix |
EP1230929A1 (en) | 1991-11-14 | 2002-08-14 | La Jolla Cancer Research Foundation | Inhibitors of cell regulatory factors and methods for preventing or reducing scarring |
WO1993010808A1 (en) | 1991-12-04 | 1993-06-10 | La Jolla Cancer Research Foundation | INHIBITING TRANSFORMING GROWTH FACTOR β TO PREVENT ACCUMULATION OF EXTRACELLULAR MATRIX |
US5824655A (en) | 1995-02-15 | 1998-10-20 | The University Of Utah | Anti-transforming growth factor-β gene therapy |
WO1997039028A1 (en) | 1996-04-12 | 1997-10-23 | American National Red Cross | Mutant plasminogen activator-inhibitor type 1 (pai-1) and uses thereof |
AU1826799A (en) | 1998-01-09 | 1999-07-26 | University Of Utah, The | Methods for preventing and treating fibrotic diseases resulting from accumulation of excess extracellular matrix induced by tgfbeta using renin inhibitors |
AU771635B2 (en) | 1999-01-05 | 2004-04-01 | American National Red Cross, The | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
EP1620128A1 (en) | 2003-04-30 | 2006-02-01 | Genzyme Corporation | Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency |
-
2004
- 2004-09-27 US US10/952,361 patent/US7763580B2/en not_active Expired - Fee Related
-
2005
- 2005-09-27 AU AU2005289518A patent/AU2005289518A1/en not_active Abandoned
- 2005-09-27 CA CA002581980A patent/CA2581980A1/en not_active Abandoned
- 2005-09-27 EP EP05812977.6A patent/EP1809742B1/en not_active Not-in-force
- 2005-09-27 WO PCT/US2005/034787 patent/WO2006037029A2/en active Application Filing
- 2005-09-27 ES ES05812977.6T patent/ES2548725T3/es active Active
- 2005-09-27 PL PL05812977T patent/PL1809742T3/pl unknown
-
2007
- 2007-10-30 US US11/981,283 patent/US20080175848A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ES2548725T3 (es) | 2015-10-20 |
EP1809742B1 (en) | 2015-07-15 |
AU2005289518A1 (en) | 2006-04-06 |
US7763580B2 (en) | 2010-07-27 |
EP1809742A2 (en) | 2007-07-25 |
WO2006037029A3 (en) | 2006-07-27 |
US20080175848A1 (en) | 2008-07-24 |
US20050124534A1 (en) | 2005-06-09 |
EP1809742A4 (en) | 2008-03-05 |
CA2581980A1 (en) | 2006-04-06 |
WO2006037029A2 (en) | 2006-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL1809742T3 (pl) | Sposoby leczenia stawów związanych z gromadzeniem nadmiaru macierzy pozakomórkowej | |
IL186895A0 (en) | Methods for treating eye conditions | |
TWI366828B (en) | Wear leveling method and controller using the same | |
GB0526291D0 (en) | Therapeutic method | |
IL198304A0 (en) | Methods for securing strand ends and the resulting devices | |
EP2105001A4 (en) | ENTERPRISE MOBILITY | |
HU0500170D0 (en) | New compounds with therapeutic effects | |
EP2083857A4 (en) | METHOD FOR TREATING INTERFERENCE IN CONNECTION WITH MICA | |
EP1912698A4 (en) | OPHTHALMIC INJECTOR SYSTEM | |
EP2041368A4 (en) | FRAME OF BLOCK OF VEGETATION AND BLOCK OF VEGETATION | |
GB2414542B (en) | Backlight unit | |
TWI348163B (en) | Wear leveling method and controller using the same | |
IL176829A0 (en) | Composition for treating pathology associated with msrv/herv-w | |
HK1118286A1 (en) | Dipyrazoles as central nervous system agents | |
EP1883405A4 (en) | METHODS OF TREATING NEPHROLITHIASIS | |
IL189244A0 (en) | Tumescent skin spacing method | |
GB0706476D0 (en) | Spectacle improvement 4 | |
GB0513872D0 (en) | Electro-optical subassembly | |
GB0408345D0 (en) | Bath n easy | |
PL381051A1 (pl) | Sposób stymulacji dojrzewania loszek | |
GB0715201D0 (en) | Flavonoids-rich tissues from neomarica gracilis and methods for culturing the same | |
GB0817436D0 (en) | The new scaffolder's level | |
GB0501925D0 (en) | Bath up | |
GB0506977D0 (en) | Bath | |
GB0513373D0 (en) | Bath |